BIOAF biOasis Technologies Inc.

biOasis Technologies, Inc. operates as a biopharmaceutical company focuses on research and development for the diagnosis and treatment of neurological disease and disorders such as brain cancers, neurodegenerative diseases, and metabolic disorders. Its products include Transcend program as its proprietary carrier, p97 and imaging agents across the blood brain barrier. The company was founded by Robin B. Hutchison on November 3, 2006 and is headquartered in Guilford, CT.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.21    OTCQB
As of 01/24/2022     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  
IPO date:  04/30/2009
Outstanding shares:  72,144,015
Average volume:  24,048
Market cap:   $15,034,813
Current dividend yield:  0.00%
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   41.68
PS ratio:   0.00
Return on equity:   429.17%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy